Your Messages Inbox
Your Article Summary
See Latest ArticlesLeukotriene Inhibitor Warning
JAMA, 07/23/09
Kuehn BM – The US Food and Drug Administration is asking manufacturers of leukotriene inhibitors to add warnings about serious psychiatric adverse events to the drugs' labels. Such drugs are approved for the treatment of asthma and allergic rhinitis.
Related Articles
New Precaution Concerning Leukotriene Inhibitors
American Journal of Nursing, 10/01/09
Relevance Score: 67%
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: Synergistic action with LY294002, an inhibitor of phosphatidylinositol 3?-kinase
Cancer Letters, 11/16/09
Relevance Score: 65%
Targeting Leukotrienes for the Treatment of COPD
Inflammation & Allergy - Drug Targets, 10/12/09
Relevance Score: 63%
Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance
Cancer Research, 11/17/09
Relevance Score: 46%
Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease
Annals of Internal Medicine, 10/20/09
Relevance Score: 45%
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor